Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

45706

Supelco

Warfarin

PESTANAL®, analytical standard

Sinonimo/i:

4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin, Coumafene

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C19H16O4
Numero CAS:
Peso molecolare:
308.33
Beilstein:
8868198
Numero CE:
Numero MDL:
Codice UNSPSC:
41116107
ID PubChem:
NACRES:
NA.24

Grado

analytical standard

Livello qualitativo

Nome Commerciale

PESTANAL®

Durata

limited shelf life, expiry date on the label

tecniche

HPLC: suitable
gas chromatography (GC): suitable

Punto di fusione

162-164 °C (lit.)

applicazioni

agriculture
environmental

Formato

neat

Stringa SMILE

CC(=O)CC(c1ccccc1)C2=C(O)c3ccccc3OC2=O

InChI

1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3
PJVWKTKQMONHTI-UHFFFAOYSA-N

Informazioni sul gene

human ... VKORC1(79001)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Warfarin is an anticoagulant commonly used in the prevention of thrombosis and thromboembolism. Its use is studied in stroke and pulmonary fibrosis patients among many others. It is used to study potential risks and interactions with other drugs and food.

Azioni biochim/fisiol

Warfarin consists of a racemic mixture of two active enantiomers, R- and S- forms. Warfarin is slower-acting than the common anticoagulant heparin. Warfarin inhibits the vitamin K-dependent synthesis of biologically active forms of the calcium-dependent clotting factors II, VII, IX and X. It inhibits regulatory factors protein C, protein S, and protein Z.

Avvertenza

Restricted to professional users. Attention − Avoid exposure − obtain special instructions before use.

Note legali

PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Non trovi il prodotto giusto?  

Prova il nostro Motore di ricerca dei prodotti.

Avvertenze

Danger

Indicazioni di pericolo

Classi di pericolo

Acute Tox. 1 Dermal - Acute Tox. 1 Inhalation - Acute Tox. 2 Oral - Aquatic Chronic 2 - Repr. 1A - STOT RE 1 Oral

Organi bersaglio

Blood

Codice della classe di stoccaggio

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe di pericolosità dell'acqua (WGK)

WGK 3


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 1

1 of 1

Jack Ansell et al.
Chest, 126(3 Suppl), 204S-233S (2004-09-24)
This article concerning the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. The article describes the antithrombotic effect of VKAs, the monitoring
A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis
Imre Noth, Kevin J. Anstrom, et al.
American Journal of Respiratory and Critical Care Medicine, 10.1164, 201202-03140C-201202-03140C (2012)
Daisuke Yoshioka et al.
Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs, 17(4), 308-314 (2014-07-23)
The aim of this study was to evaluate our clinical experience with the Jarvik 2000 axial flow pump (Jarvik Heart, Inc, New York, NY, USA), a miniature axial flow left ventricular assist device (LVAD). The clinical results of eight patients
Periprocedural management of new oral anticoagulants in patients undergoing atrial fibrillation ablation.
Jeffrey I Weitz et al.
Circulation, 129(16), 1688-1694 (2014-04-23)
James D Douketis et al.
Thrombosis and haemostasis, 113(3), 625-632 (2014-12-05)
In patients with atrial fibrillation (AF) who require interruption of dabigatran or warfarin for an elective surgery/procedure, the risks and benefits of perioperative bridging anticoagulation is uncertain.We accessed the database from RE-LY, a randomised trial comparing dabigatran with warfarin for

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.